Genentech

TECENTRIQ

Manufacturer:

Genentech

Tecentriq HCPCS:

J9022

HCPCS Code Descriptor:

Injection, atezolizumab, 10 mg

Category:

J Code

Tecentriq NDCs:

50242-0918-01, 50242-0917-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tecentriq:

TECENTRIQ is an Oncology drug manufactured by Genentech and administered via the Intravenous route of administration. The J Code: J9022 is aligned to the drug TECENTRIQ.

TECENTRIQ is a monoclonal antibody used to treat non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. It works by binding programmed death ligand 1, which may be expressed on tumor cells and can contribute to the inhibition of the anti-tumor response. When TECENTRIQ (J9022) binds PD L1, prevents it from interacting with programmed death ligand (PD1) and allows the immune response against the tumor to proceed. TECENTRIQ may be used to treat anyone over the age of 2. Patient assistance for this medication is available through the Genentech Foundation.

ACCESS PRICING AND MORE BY REGISTERING

J9022 Added Date:

January 1, 2018

J9022 Effective Date:

January 1, 2018

J9022 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Tecentriq billing and coding information.
Tecentriq patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
TECENTRIQ prescribing information can be found at the link below:
Information regarding TECENTRIQ’s side effects can be found at MedlinePlus